

1           **Evaluation of recombinant nucleocapsid and spike proteins for**  
2           **serological diagnosis of novel coronavirus disease 2019 (COVID-19)**

3                           **Running title:** Diagnostic tools for COVID-19 infections

4   Pingping Zhang<sup>1,2,#</sup>, Qi Gao<sup>2,3,#</sup>, Tang Wang<sup>4,#</sup>, Yuehua Ke<sup>5</sup>, Fei Mo<sup>6,7</sup>, Ruizhong  
5   Jia<sup>5</sup>, Wanbing Liu<sup>8</sup>, Lei Liu<sup>8</sup>, Shangen Zheng<sup>8</sup>, Yuzhen Liu<sup>9</sup>, Luping Li<sup>10</sup>, Yao Wang<sup>11</sup>,  
6   Lei Xu<sup>2,3</sup>, Kun Hao<sup>2,3</sup>, Ruifu Yang<sup>1,2,\$</sup>, Shiyue Li<sup>4,\*</sup>, Changqing Lin<sup>2,3,\*</sup>, Yong  
7   Zhao<sup>1,2,\*</sup>

8

9   <sup>1</sup> State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology  
10 and Epidemiology, Beijing 100071, P. R. China

11   <sup>2</sup> Beijing Key Laboratory of POCT for Bioemergency and Clinic (No. BZ0329),  
12 Beijing 100071, P. R. China

13   <sup>3</sup> Beijing Hotgen Biotechnology Inc., Beijing 100071, P. R. China

14   <sup>4</sup> Wuhan University School of Health Sciences, P. R. China

15   <sup>5</sup> Huoshenshan Hospital, Wuhan, P. R. China

16   <sup>6</sup> Center for Clinical Laboratories, Affiliated Hospital of Guizhou Medical University,  
17 Guiyang 550004, P. R. China

18   <sup>7</sup> Department of Basic Clinical Laboratory Medicine, School of Clinical Laboratory  
19 Science, Guizhou Medical University, Guiyang 550004, P. R. China

20   <sup>8</sup> General Hospital of Central Theater Command of the PLA, Wuhan, P. R. China

21   <sup>9</sup> Shijiazhuang Fifth Hospital, Shijiazhuang 050023, P. R. China

1 <sup>10</sup>The Sixth People's Hospital of Shenyang, P. R. China

2 <sup>11</sup> Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking

3 Union Medical College, Chinese Academy of Medical Sciences, P. R. China

4

5 # These authors contributed equally to this work.

6 \$ Senior author

7 \*Corresponding authors:

8 Yong Zhao: zhaoyong179@139.com

9 Changqing Lin: changqing.lin@hotmail.com.cn

10 Shiyue Li: lsywhd@sina.com

1 **Abstract**

2 **Background:** The colloidal gold immunochromatography assay (GICA) is a rapid  
3 diagnostic tool for novel coronavirus disease 2019 (COVID-19) infections. However,  
4 with significant numbers of false negatives, improvements to GICA are needed.

5 **Methods:** Six recombinant HCoV-19 nucleocapsid and spike proteins were prepared  
6 and evaluated. The optimal proteins were employed to develop a sandwich-format  
7 GICA strip to detect total antibodies (IgM and IgG) against HCoV-19. GICA's  
8 performance was assessed with comparison of viral RNA detection.

9 **Results:** Recombinant HCoV-19 proteins were obtained, including three  
10 prokaryotically expressed rN, rN1, rN2 nucleocapsid proteins, and three  
11 eukaryotically expressed rS1, rS-RBD, rS-RBD-mFc spike proteins. The recombinant  
12 proteins with the highest ELISA titers (rS1 and rS-RBD-mFc) against  
13 coronavirus-specific IgM and IgG were chosen for GICA development. The GICA  
14 has a sensitivity and specificity of 86.89% (106/122) and 99.39% (656/660),  
15 respectively. Furthermore, 65.63% (21/32) of the clinically confirmed but RT-PCR  
16 negative samples were GICA positive.

17 **Conclusions:** The eukaryotically-expressed spike proteins (rS1 and rS-RBD-mFc) are  
18 more suitable than the prokaryotically expressed nucleocapsid proteins for HCoV-19  
19 serological diagnosis. The GICA sandwich used to detect total antibodies is a  
20 powerful complement to the current standard RNA-based tests.

21 **Keywords:** HCoV-19 (SARS-CoV-2), Recombinant protein, Eukaryotic expression,  
22 Serological diagnosis, Colloidal gold immunochromatography assay (GICA)

## 1 **Introduction**

2 The recent coronavirus disease 2019 (COVID-19) outbreak has been classified as a  
3 global pandemic on March 12, 2020, which continues to pose a great threat to global  
4 public health. The disease is caused by a novel coronavirus, called 2019-nCoV by the  
5 World Health Organization at the beginning of the outbreak, and latterly, severe acute  
6 respiratory syndrome coronavirus 2 (SARS-CoV-2) by the ICTV (International  
7 Committee on Taxonomy of Viruses) [1]. However, this name is prone to confusion  
8 with SARS-CoV, which emerged in 2003, and a suggestion for a distinct name was  
9 proposed, human coronavirus 2019 (HCoV-19) [2]. This novel virus is potentially  
10 more transmissible than SARS-CoV and other coronavirus [3], making early  
11 diagnosis of it important for clinical treatment and disease control. However, the  
12 current nucleic acid testing approach for HCoV-19 [4] carries a negligible  
13 false-negative risk [5]. Serological assays are supposedly a powerful approach for  
14 achieving timely diagnosis of COVID-19, as is nucleic acid testing, especially for  
15 patients with undetectable viral RNA [6]. The serological assays used for early  
16 diagnosis are mainly based on detecting specific antibodies against HCoV-19 in a  
17 patient's serum and include the enzyme-linked immunosorbent assay (ELISA), the  
18 colloidal gold immunochromatography assay (GICA) and the chemiluminescence  
19 assay.

20 To develop a reliable serological assay, it is important to obtain suitable HCoV-19  
21 antigens or related recombinant proteins. HCoV-19 is a  $\beta$  family coronavirus, with a

1 spike protein (S protein), envelope protein (E), membrane protein (M), and  
2 nucleocapsid protein (N protein). Among them, the N-protein is the most abundant,  
3 relatively conservative protein in coronaviruses; thus, it is often used as a diagnostic  
4 antigen [7]. Our previous study showed that the antigenicity of the COOH terminus is  
5 higher than that of the NH<sub>2</sub> terminus in the SARS-CoV N protein, and that the former  
6 N protein fragment may have the same antigenicity as that seen with the full-length N  
7 protein [8]. In contrast, the S protein is the common target when designing vaccines  
8 based on neutralizing antibodies. It contains a receptor binding domain (S-RBD) in  
9 the S1 subunit, which mediates receptor binding and membrane fusion [9, 10].  
10 Recently, S-RBD from HCoV-19 was reported to have higher affinity than  
11 SARS-CoV to angiotensin-converting enzyme 2, and also to lack cross-reactivity with  
12 monoclonal antibodies against S-RBD from SARS-CoV [3], highlighting the potential  
13 value of the S protein for diagnosing HCoV-19. As a transmembrane protein with  
14 hydrophobic regions, the S protein is better prepared using a eukaryotic expression  
15 system.

16 In the present study, we prepared six recombinant proteins based on the reported  
17 HCoV-19 sequence (GenBank accession MN908947) [11]. Three recombinant N  
18 proteins were obtained by prokaryotic expression, including the full-length  
19 recombinant N protein (rN), NH<sub>2</sub> terminal (rN1) protein fragments, and COOH  
20 terminal (rN2) fragments from this protein. Three recombinant S proteins were also  
21 obtained by eukaryotic expression, including an S1 domain (rS1) fragment, the

1 receptor binding domain (rS-RBD), and S-RBD ligated to the Fc fragment from  
2 mouse (rS-RBD-mFc). The recombinant proteins were evaluated using indirect  
3 ELISA. Two recombinant proteins with the highest ELISA titers (rS1 and  
4 rS-RBD-mFc) were chosen to develop a sandwich-format GICA strip to detect total  
5 antibodies (IgM and IgG) against HCoV-19. The performance of the GICA strip,  
6 which was evaluated with 814 clinical samples, showed a high detection sensitivity  
7 (86.89%) and specificity (99.39%) with samples from COVID-19-infected patients.

8

## 9 **Materials and Methods**

### 10 **Ethics statement**

11 This study was approved by the Medical Ethical Committee of Peking Union  
12 Medical College Hospital (approval number 002285), General Hospital of Central  
13 Theater Command of the PLA (approval number 2020-003-1), and Shijiazhuang  
14 Fifth Hospital (approval number 2020-002). Written informed consent from all the  
15 patients was obtained, and all records and information on the patients were  
16 anonymized.

### 17 **Materials**

18 DNA polymerase (2×Pfu MasterMix) was purchased from Beijing TransGen  
19 Biotech (Beijing, China). T4 DNA ligase and Gibson Assembly kit were from New  
20 England BioLabs Inc., (Ipswich, England). Eukaryotic vectors H293 and H293-Fc,  
21 which were used for transient expression, were obtained from the Laboratory of

1 Protein Project, Beijing Institute of Biotechnology, China. FreeStyle™ 293 expression  
2 medium, Opti-MEM® I (1×), a reduced serum medium, and 293 fectin™ reagents  
3 were purchased from Invitrogen Inc., (CA, Carlsbad, USA). The Unique CDSsystem  
4 for protein purification was from Suzhou Inscinotech Co., Ltd. (Suzhou, China). The  
5 DNA extraction/purification kit was from Beijing TransGen Biotech. Primer  
6 construction and sequencing work were conducted by Beijing Tianyi Huiyuan Biotech  
7 Ltd., and Beijing Biomed Biotech Ltd., respectively. GICA nitrocellulose (NC)  
8 membranes were obtained from MilliporeSigma. (Saint Louis, MO, USA), glass fiber  
9 and absorbent pads were from Shanghai Kinbio Tech. Co., Ltd. (Shanghai, China).

10 The gene sequences of the recombinant proteins were all derived from the RNA  
11 sequence of HCoV-19 strain from Wuhan (GenBank accession MN908947). The  
12 nucleotide positions of the gene sequences are rS1 (21602–23584), rS-RBD  
13 (22514–23311), rN (28274–29530), rN1 (28274–28900), and rN2 (28901–29530).  
14 The N, N1, and N2 gene cloning vectors were constructed by General Biosystems Co.,  
15 Ltd (Anhui, China). The S1 DNA sequence was optimized and synthesized by  
16 GenScript Co., Ltd (Nanjing, China). The vector and bacterial strains for prokaryotic  
17 expression were pET28a, *E. coli* Rosetta or BL21(DE3).

18 **Gene subcloning, eukaryotic expression vector construction, and protein**  
19 **expression and purification of rS1, rS-RBD-mFc and rS-RBD**

20 The full coding region, which was obtained by overlapping extension PCR using  
21 primers containing restriction enzyme recognition sites (Table 1), was ligated to

1 HEK293 vectors after digestion. The recombinant plasmids were transformed into *E.*  
2 *coli* DH5 $\alpha$ , and bacterial colonies were selected on Luria-Bertani (LB) agar  
3 containing ampicillin. Positive colonies were cultured in 500  $\mu$ L LB liquid medium  
4 for 2–4 h, and the resultant plasmids were extracted, PCR-verified, and sequenced.  
5 Positive recombinant plasmids (210  $\mu$ g each) and liposomes (280  $\mu$ L) were diluted in  
6 7 mL of opti-MEM medium for 5 min, respectively, mixed for 30 min and H293 cells  
7 ( $1.2 \times 10^6$  /mL) were added. After culturing (120 rpm, 37°C with 5% CO<sub>2</sub>, 3–4 days),  
8 the cell supernatants collected by centrifugation were purified with a 0.44- $\mu$ m filter  
9 and the Unique CDSystem chromatography workstation. After column Protein A  
10 balancing (10 column volumes) with phosphate-buffered saline (PBS), the cell  
11 supernatants were placed under a flow rate of 2.0 ml/min, and then washed and eluted  
12 with PBS (five column volumes) and citric acid buffer (pH 3.0) to collect the purified  
13 protein. For desalination, a 1/3 sample volume was applied to a G25 column  
14 pre-balanced with PBS (5 column volumes), and each protein was collected after  
15 column washes with PBS. Their purities were confirmed by sodium dodecyl  
16 sulfate–polyacrylamide gel electrophoresis (SDS-PAGE).

17 **Gene subcloning, expression vector construction, protein expression and**  
18 **purification of rN, rN1 and rN2**

19 The N protein's full coding region was PCR amplified using primers containing  
20 restriction enzyme recognition sites (Table 1). The restricted amplicons were ligated  
21 into pET28a or pET32a using T4 DNA ligase. The recombinant plasmids were



1 transformed into *E. Coli* Rosetta or BL21 (DE3), and the bacterial colonies were  
2 selected on LB agar containing kanamycin. Recombinant plasmids in the bacterial  
3 colonies were extracted and confirmed as authentic by DNA sequencing. Protein  
4 expression was induced for 5 h in positive bacterial colonies with 0.5 mM  
5 isopropyl-D-thiogalactopyranoside (IPTG) at a starting optical density (OD) of 0.6.  
6 After centrifugation, the supernatants and precipitation products from the lysed  
7 bacteria were analyzed by SDS-PAGE. The rN, rN1 and rN2 recombinant proteins  
8 were produced by the bacteria harboring the recombinant plasmids via IPTG  
9 induction in 2 L of LB medium (20°C, 200 × g, 10 h), and the bacteria were harvested  
10 and lysed by ultrasonication (300 W, 30 min). The supernatants were clarified by  
11 centrifugation (10,000 × g, 20 min), filtrated (0.4-µm filter membrane), and run  
12 through a 3 mL Ni Sepharose column with 30 ml lysis buffer, and then washed  
13 extensively with PBS containing imidazole (20–80 mM gradient) to remove  
14 non-specific proteins. The target proteins were eluted with PBS containing 250 mM  
15 imidazole.

16 [Table 1]

### 17 **Preliminary evaluation of recombinant proteins by ELISA**

18 The recombinant proteins were initially evaluated by indirect ELISA. After coating  
19 the wells with the prepared recombinant proteins, 50µL of serially diluted human  
20 samples were added to the wells and mixed with 50µL of horseradish peroxidase  
21 (HRP)-labeled goat anti-human IgM or IgG, followed by incubation (37°C, 60 min).

1 After the solution was removed and the wells had been washed with PBS buffer  
2 containing Tween-20 five times, 50  $\mu$ L of tetramethylbenzidine substrate was added to  
3 the wells in the plate for 15 min. OD values were measured on a microplate reader  
4 (450/630 nm), and recombinant proteins with high OD values for COVID-19 patient  
5 serum and low OD reads for the negative control serum were used for all further  
6 experiments.

7 ELISA plates coated with the six recombinant proteins were first tested with seven  
8 negative sera from healthy people. Their average values plus two-fold standard  
9 deviations (MEAN+2SD) were used as the cutoffs. However, they were not  
10 completely equivalent for each protein and some were set at 0.2 when the calculated  
11 values were below 0.2. Sera from two patients with COVID-19 were diluted at ratios  
12 of 1:800, 1:400 and 1:100 for IgM detection, and ratio of 1:80, 1:40 and 1:20 for IgG  
13 detection. The average value (MEAN) from the negative serum samples was set as the  
14 background value, and the lowest antibody titer with a value higher than the cutoff  
15 was set as the sensitivity level.

#### 16 **Preparing the GICA strip with recombinant proteins for antibody detection**

17 Colloidal gold suspension was prepared by reducing gold chloride with citrate. The  
18 colloidal gold was conjugated to recombinant protein rS-RBD. Briefly, 1 mg of  
19 rS-RBD was added to 100 mL of the colloidal gold suspension. After a 30 min  
20 reaction, conjugation was blocked using 10 mL of 10% bovine serum albumin (BSA)

1 for 15 min. The colloidal gold conjugate collected (centrifugation at 12,000 rpm, 30  
2 min, 4°C) was resuspended in PBS containing 0.1% BSA and 0.1% Tween-20.

3 The colloidal gold and rS-RBD (0.5 mg/mL) conjugate was applied to a conjugate  
4 pad (glass fiber) (30 µL/cm, dried at 37 °C, 3 h). Using a dispenser (XYZ3000;  
5 BioDot, Irvine, CA), rS1 and the secondary polyclonal antibody (2 mg/mL) were  
6 coated onto the nitrocellulose membrane as the test and control lines, respectively, at a  
7 dispensing rate of 1.0 µL/cm. The membrane was then dried at 37 °C for 1 h. Finally,  
8 the nitrocellulose membrane, conjugate pad, sample pad and the absorbent pads were  
9 assembled and cut into 4-mm strips.

#### 10 **Evaluating the GICA strips**

11 A positive serum sample was serially diluted with running buffer at a ratio of  
12 1:10–1:320. The limit of detection of the GICA strip was determined using 100 µL of  
13 the sample, and 0.9% NaCl was used as the blank control. The results could be  
14 obtained by naked eyes after 5-10 min. Each test was repeated three times.  
15 Additionally, 41 serially-diluted samples collected from healthy men were tested to  
16 evaluate the specificity of the GICA strips.

17 Another 814 serum samples from patients suspected of harboring COVID-19  
18 infections were collected from Huoshenshan Hospital, General Hospital of Central  
19 Theater Command of the PLA, the Sixth People's Hospital of Shenyang, Peking  
20 Union Medical College Hospital, and Shijiazhuang Fifth Hospital in China. All  
21 samples were tested on the GICA strips, along with PCR tests on nasal/pharyngeal

1 swab for comparison. PCRs were performed with officially approved real-time PCR  
2 (RT-PCR) kits.

3

## 4 **Results**

### 5 **Acquisition of the six recombinant proteins**

6 Through gene subcloning by overlapping extension PCR and ligation to the HEK  
7 293 vector, the S1, S-RBD-mFc (containing the mouse Fc fragment) and S-RBD  
8 recombinant plasmids were constructed and verified by PCR and sequencing (Figure  
9 1A). Following lipofection, transient expression in eukaryotic HEK293 cells and  
10 protein purification, highly pure rS1, rS-RBD-mFc and rS-RBD were obtained  
11 (Figure 1D).

12 Through gene subcloning and ligation to the pET vector, recombinant N, N1 and  
13 N2 plasmids were constructed and verified by PCR and sequencing (Figure 1B and C).  
14 The rN, rN1 and rN2 expression products from IPTG induction at 37°C in *E. coli*  
15 were identified in the culture supernatants and in the precipitates (Figure 1E and F),  
16 so the induction temperature was lowered to 20°C, which increased the protein in the  
17 supernatants significantly. The supernatant proteins were purified and used for  
18 subsequent studies (Figure 1E and F). That the HCoV-19 N proteins were present in  
19 the precipitates implies that their expression in *E. coli* may influence their accurate  
20 folding or conformation, because the viral N protein may be conformationally

1 modified after transcription in human cells. Overall, six high-yield recombinant  
2 proteins from HCoV-19 with high purities were obtained, as summarized in Table 2.

3 [Figure 1]

4 [Table 2]

### 5 **Preliminary ELISA evaluation of recombinant proteins**

6 Indirect ELISAs were used to preliminarily evaluate the six recombinant proteins.

7 Using serum samples from seven healthy people as the negative controls, serial

8 samples from two patients in the acute phase (<7 days after symptom onset) of

9 COVID-19 were detected. For the S proteins, the coefficient of variation (CV) for the

10 seven negative samples was 20%–30%. For the N proteins, the CV was 74%–92%,

11 resulting in a high cutoff value.

12 For IgM detection, all the S proteins had lower background values and higher OD

13 values than those of the N proteins, as well as higher sensitivities (1:800) (Figure 2A

14 and 2C). For IgG detection, rS-RBD-mFc had the highest sensitivity (1:80), while the

15 second highest sensitivity (1:40) was attained by rS1, rS-RBD and rN (Figure 2B and

16 2D). Although with the same sensitivity and similar background, rS1 produced a

17 higher OD value than rS-RBD. The better performance of rS-RBD-mFc when

18 compared with rS-RBD may be related to the protein Fc fragments, which can

19 increase the half-life and stability for the RBD protein fragment from the S protein.

20 Overall, rS-RBD-mFc and rS1 were best suited for IgM and IgG detection.

1 The IgM-specific sensitivities for ELISA (from 1:100 to 1:800) are all higher than  
2 those for IgG (1:20–1:80), mostly because the positive serial samples came from  
3 patients during the acute phase of COVID-19 infection. Additionally, the antigenicity  
4 of full-length rN was higher than that of fragments rN1 and rN2, which is consistent  
5 with the findings from our previous study on SARS-CoV [8]. However, the higher  
6 sensitivity of rN1 over rN2 suggests that the antigenicity of the protein fragment at  
7 the NH<sub>2</sub> terminus of the N protein was higher than that at the COOH terminus, which  
8 is the opposite result of our previous study on SARS-CoV [8].

9 [Figure 2]

#### 10 **Recombinant protein evaluation by GICA tests**

11 As shown in Figure 3, a double-antigen sandwich-format GICA strip developed  
12 with recombinant rS-RBD and rS1 proteins was used to detect total antibodies (IgM  
13 and IgG) against HCoV-19 in serum samples. Positive results were observed at a  
14 1:160 dilution of the patient serum, indicating that the GICA strip was able to detect  
15 low- titer antibodies in serum. Moreover, several samples from patients infected with  
16 influenza A, influenza B, respiratory syncytial virus, *Mycoplasma pneumoniae*, and  
17 *Chlamydia pneumoniae* were all tested by GICA. No cross-reactions were observed  
18 with these samples. An additional 41 serum samples from healthy people were all  
19 negatively detected by the GICA strips, demonstrating good specificity for the  
20 rS-RBD- and rS1-based serological methods.

21 [Figure 3]

## 1 **GICA strip performances on serum samples**

2 Altogether, 814 serum samples from HCoV-19-suspected patients were tested on  
3 GICA strips, including 122 patients confirmed to be RT-PCR positive, 660 confirmed  
4 to be RT-PCR negative, and 32 confirmed to be RT-PCR negative but clinically  
5 diagnosed by computed tomography (CT). The positive coincidence and negative  
6 coincidence rates between GICA and RT-PCR were 86.89% and 99.39%, respectively  
7 (Table 3). Moreover, among the 32 RT-PCR negative clinically diagnosed samples, 21  
8 (65.63%) were detectable by GICA. This shows that GICA has a high coincidence  
9 rate with RT-PCR tests and also complements the PCR negative, clinically diagnosed  
10 cases, providing a potentially powerful serological tool for diagnosing COVID-19 in  
11 patients.

12

## 13 **Discussion**

14 Rapid detection methods are urgently required for the early diagnosis of patients  
15 with fever [10, 12, 13], and for pre-symptomatic or asymptomatic carriers infected  
16 with HCoV-19 [12, 14]. However, nucleic acid-based molecular diagnosis tools (e.g.,  
17 real-time PCR and loop-mediated isothermal amplification), depend on there being a  
18 sufficient viral load in the patient's upper respiratory tract and reasonable sample  
19 quality. In the early infection stages, human antibodies, especially IgM, can reach a  
20 high level during the immune response to viral invasion. Therefore, serological testing

1 is important for early COVID-19 diagnosis, especially for patients with undetectable  
2 viral RNA [10].

3 Selecting suitable recombinant HCoV-19 proteins for reliable serological assays is  
4 crucial. Some cross-reactive N proteins from another coronavirus were serologically  
5 investigated to meet the rapidly developing HCoV-19 emergency [9, 15]; however,  
6 the divergent receptor binding protein spike gene in other CoVs [9], as well as the  
7 high antigenicity of the receptor binding domain of HCoV-19 [3] emphasized the  
8 necessity to research HCoV-19 antigens more comprehensively. Consequently, in the  
9 present study, we prepared six recombinant proteins, including three S proteins (rS1,  
10 rS-RBD, rS-RBD-mFc) and three N proteins (rN, rN1, rN2). Because the S protein is  
11 a transmembrane protein, three S protein fragments were prepared using a eukaryotic  
12 expression system, while three N proteins were prepared using a prokaryotic  
13 expression system. Preliminary evaluation by indirect ELISA revealed that the three S  
14 proteins were superior in performance to the three N proteins. Thus, it can be inferred  
15 that the eukaryotically expressed HCOV-19 recombinant S protein is suitable for  
16 detection of antibodies from COVID-19 patients for early diagnosis, and is superior to  
17 the N protein prepared by prokaryotic expression. However, the antigenicity of S  
18 proteins and that of the N proteins could not be confirmed in this study, because the  
19 influence of prokaryotic expression method used to produce the N proteins is difficult  
20 to predict. The prokaryotically expressed recombinant N proteins were all insoluble  
21 precipitates, especially rN2, making it likely that their natural conformations were lost



1 or they were not normally modified. Thus, the N protein's antigenicity should be  
2 studied after expression in a eukaryotic system in future.

3 GICA, a simple and rapid serological method, is especially suitable for timely  
4 diagnosis and large-scale sample screening. A recent study showed that the sensitivity  
5 of the total antibody (IgM and IgG) test is higher than that of the IgM or IgG test [16].

6 Therefore, we developed a sandwich-format GICA with rS1 and rS-RBD-mFc to  
7 detect total antibodies in patient serum. The GICA tests were highly sensitive  
8 (86.89%) and specific (99.39%), which should help with diagnosing COVID-19 in  
9 RT-PCR-negative patients who are clinically confirmed COVID-19 positive by CT.

10 The detection sensitivity will be improved if we eliminate the sera from patients  
11 within the 5 days of symptoms onset.

12

### 13 **Conclusions**

14 In the study, six recombinant HCoV-19 proteins were prepared and selected. It  
15 showed that the eukaryotically-expressed spike proteins (rS1 and rS-RBD-mFc) are  
16 more suitable than the prokaryotically expressed nucleocapsid proteins for HCoV-19  
17 serological diagnosis. The provided recombinant proteins could be used for  
18 development of serological diagnostic tools for COVID-19 infections. Here, A  
19 sandwich-format GICA strip with the recombinant proteins was developed to detect  
20 total antibodies (IgM and IgG) against HCoV-19. The assay was shown to be a rapid

1 (10 min), simple, and highly sensitive diagnostic tool, providing a potentially

2 powerful serological method for diagnosing COVID-19.

3

1 **Notes**

2 **Acknowledgments**

3 We thank the clinical study investigators and volunteers. We thank for our  
4 collaborators in the Laboratory of Protein Project, Beijing Institute of Biotechnology,  
5 for providing the eukaryotic vectors.

6 **Financial support**

7 Funding for this study was provided by The National Key Research and  
8 Development Program of China (Grant No. 2018YFC1200502), and The National  
9 Science and Technology Major Project (Grant No. 2018ZX10101003-002).

10 **Potential conflicts of interest**

11 All authors: No reported conflicts of interest. All authors have submitted the  
12 ICMJE Form for Disclosure of Potential Conflicts of Interest.

13 **No part of the information has previously been presented in any meetings.**

14 **Correspondence**

15 Y. Z, Dr., Beijing Institute of Microbiology and Epidemiology, No. 20, Dongdajie  
16 street, Fengtai district, Beijing 100071, P. R. China ([zhaoyong179@139.com](mailto:zhaoyong179@139.com))

17 C. L., Mr., Beijing Key Laboratory of POCT for Bioemergency and Clinic (No.  
18 BZ0329), Beijing 100071, P. R. China ([changqing.lin@hotgen.com.cn](mailto:changqing.lin@hotgen.com.cn))

19 S. L., Dr., Wuhan University School of Health Sciences, Wuhan 430071, P. R. China  
20 ([lsywhd@sina.com](mailto:lsywhd@sina.com))

21

## 1   **References**

- 2       1. Coronaviridae Study Group of the International Committee on Taxonomy of V.  
3           The species Severe acute respiratory syndrome-related coronavirus: classifying  
4           2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol* **2020**.
- 5       2. Jiang S, Shi Z, Shu Y, et al. A distinct name is needed for the new coronavirus.  
6           *Lancet* **2020**.
- 7       3. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike  
8           in the prefusion conformation. *Science* **2020**.
- 9       4. Chu DKW, Pan Y, Cheng SMS, et al. Molecular Diagnosis of a Novel  
10           Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. *Clinical*  
11           *Chemistry* **2020**.
- 12       5. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of  
13           2019-nCoV infected patients: implication of multiple shedding routes. *Emerg*  
14           *Microbes Infect* **2020**; 9:386-9.
- 15       6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019  
16           novel coronavirus in Wuhan, China. *Lancet* **2020**; 395:497-506.
- 17       7. Seo SH, Wang L, Smith R, Collisson EW. The carboxyl-terminal 120-residue  
18           polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T  
19           lymphocytes and protects chickens from acute infection. *J Virol* **1997**;  
20           71:7889-94.

- 1 8. Chen Z, Pei D, Jiang L, et al. Antigenicity analysis of different regions of the  
2 severe acute respiratory syndrome coronavirus nucleocapsid protein. *Clin Chem*  
3 **2004**; 50:988-95.
- 4 9. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new  
5 coronavirus of probable bat origin. *Nature* **2020**.
- 6 10. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019  
7 novel coronavirus: implications for virus origins and receptor binding. *Lancet*  
8 **2020**; 395:565-74.
- 9 11. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory  
10 disease in China. *Nature* **2020**.
- 11 12. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of  
12 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive  
13 study. *Lancet* **2020**; 395:507-13.
- 14 13. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients  
15 With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*  
16 **2020**.
- 17 14. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of  
18 COVID-19. *JAMA* **2020**.
- 19 15. Wang N, Li SY, Yang XL, et al. Serological Evidence of Bat SARS-Related  
20 Coronavirus Infection in Humans, China. *Virol Sin* **2018**; 33:104-7.
- 21 16. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients  
22 of novel coronavirus disease 2019. *medRxiv* **2020**:2020.03.02.20030189.

23

1 **Figure Captions**

2 **Figure 1.** Gene fragments and purified recombinant HCoV-19 proteins analyzed by  
3 agarose electrophoresis and SDS-PAGE. (A) PCR identification of S1 and  
4 S-RBD-mFc gene fragments. (B) N gene fragment. (C) N2 gene fragment. (D)  
5 SDS-PAGE for purified rS1 and rS-RBD-mFc. (E) SDS-PAGE for rN. Lanes 1 and 2  
6 are the precipitant and supernatant, respectively, from crude *E. coli* extracts  
7 harboring the recombinant plasmid. Lanes 3–8: Ni Sepharose affinity column  
8 purification. Lane 3 shows unbound proteins. Lanes 4–7: proteins washed from the  
9 column using 10, 20, 60 and 80 mM imidazole. Lane 8 is rN eluted with 250 mM  
10 imidazole. (F) SDS-PAGE for rN2. Lanes 1 and 2 are the supernatant and  
11 precipitant, respectively, from crude *E. coli* extracts harboring the recombinant  
12 plasmid. Lanes 3– 9: Ni Sepharose affinity column purification. Lane 3 shows the  
13 unpurified supernatant proteins. Lanes 4–7: Proteins washed from the column using  
14 10, 20, 20 and 50 mM imidazole. Lanes 8–9: rN eluted in 250 mM imidazole.




15

16 **Figure 2.** Evaluation of recombinant HCOV-19 proteins by indirect ELISA on serum  
17 samples. Serum samples from seven healthy people and two COVID-19 patients (P1  
18 and P2) were used as negative controls and positive samples, respectively. (A) IgM  
19 detection in serum samples by the recombinant S1 domain protein fragment from  
20 the HCoV-19 spike protein (rS1), the receptor binding domain of the S protein  
21 (rS-RBD), and S-RBD ligated to the Fc fragment from mouse (rS-RBD-mFc)





1 following their expression in a eukaryotic system. (B) IgG detection in serum samples  
2 using rS1, rS-RBD and rS-RBD-mFc proteins. (C) IgM detection in serum samples  
3 using full-length recombinant nucleocapsid protein (rN), an NH<sub>2</sub> recombinant  
4 fragment from the N (rN1) or COOH (rN2) termini following their expression in a  
5 prokaryotic system. (D) IgG detection in serum samples using rN, rN1 and rN2  
6 proteins. Dashed lines, cutoff values.




7

8 **Figure 3.** (A) Schematic illustration of the sandwich-format GICA strip for IgM and  
9 IgG antibody detection against HCoV-19. (B) Lower detection limit of the GICA strip,  
10 as determined with serial dilutions of the positive serum. (C) Cross-reaction testing of  
11 the GICA strip with other respiratory diseases.









1-HCoV-19  
 2-Influenza A  
 3-Influenza B  
 4-RSV  
 5-*M. pneumoniae*  
 6-*C. pneumoniae*

1 **Tables**

2 **Table 1. Subcloning primers for preparation of the recombinant proteins**

<b>Primer</b>	<b>Sequence</b>
<b>S1-F</b>	GCGAATTCGCCGCCACCATGTTTCGTGTTTCTGGTGCTGC
<b>S1-R</b>	GGGGATCCCTAGTGATGGTGATGGTGATGGTAGGAGGCAC AGATGCCGG
<b>S-RBD-mFc-F</b>	TCCTTAAGGGCGTGCAGTGCATGTTCTTGTTAACAATAA ACGAACAATGTTTG
<b>S-RBD-mFc-R</b>	TCGCTAGCACGTGCCCGCCGAGGAGAATTAG
<b>S-RBD-F</b>	TCCTTAAGGGCGTGCAGTGCAATATTACAACTTGTGCC TTTTGG
<b>S-RBD-R</b>	CTGGATCCCTAGTGATGGTGATGGTGATGCTCAAGTGCT GTGGATCACGG
<b>N-F</b>	GAAGGAGATATAACCATGGGCATGTCTGATAATGGACCCCA
<b>N-R</b>	TGGTGGTGGTGGTGCTCGAGGGCCTGAGTTGAGTCAGCA
<b>N1-F</b>	CGGGATCCCGAATGTCTGATAATGGACC
<b>N1-R</b>	CCCAAGCTTTCTAGCAGGAGAAGTTCCCCTAC
<b>N2-F</b>	GAAGGAGATATAACCATGGGCATGGCTGGCAATGGCGGTGA TGCTGCTCTT
<b>N2-R</b>	CCGCTCGAGGGCCTGAGTTGAGTCAGCACTGCTC

3 Underlined letters: restriction enzyme recognition sites.

1 **Table 2. Information of the prepared recombinant proteins**

<b>Recombinant protein</b>	<b>Tag<sup>a</sup></b>	<b>Amino acid</b>	<b>MW<sup>b</sup> (kDa)</b>	<b>Expression</b>	<b>Strain<sup>c</sup></b>	<b>Restriction site<sup>d</sup></b>
<b>rS1-His</b>	His	667	76.5	Eukaryotic	HEK 293	Afl II/Nhe I
<b>rS-RBD-mFc</b>	His	501	63	Eukaryotic	HEK 293	Afl II/Nhe I
<b>rS-RBD</b>	His	259	30	Eukaryotic	HEK 293	Afl II/Nhe I
<b>rN</b>	His	428	45	Prokaryotic (pET28a)	<i>E.coli</i> Rosetta	NcoI/XhoI
<b>rN1</b>	Sumo, His	273	47	Prokaryotic (pET28a)	<i>E.coli</i> BL21	HindIII/ BamHI
<b>rN2</b>	TrxA, His	210	43	Prokaryotic (pET32a)	<i>E.coli</i> BL21	NcoI/XhoI

2 <sup>a</sup>Protein tags. Sumo and TrxA tags are 18 and 20 kDa, respectively.

3 <sup>b</sup> Molecular weight of the recombinant protein including the tags.

4 <sup>c</sup> Strains used for engineering and protein expression

5 <sup>d</sup> Restriction enzyme recognition sites

6

1 **Table 3. GICA strip results of the serum samples**

<b>Group</b>	<b>Total</b>	<b>GICA detection results (%)</b>	
		<b>Positive</b>	<b>Negative</b>
<b>RT-PCR Positive</b>	122	106 (86.89%)	16 (13.11%)
<b>RT-PCR Negative</b>	660	4 (0.61%)	656 (99.39%)
<b>Clinically confirmed</b>	32	21 (65.63%)	11 (35.37%)

2

3